Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chemokine-like protein TAFA-4 (TAFA4) is a member of the TAFA/FAM19A family of small, secreted proteins structurally related to CC-chemokines and expressed primarily in the nervous system, including dorsal root ganglia nociceptors[1][2]. TAFA-4 has key roles in modulating pain sensitivity and is a ligand for the G protein-coupled formyl peptide receptor 1 (FPR1), mediating chemotaxis and activation of immune cells such as macrophages as well as influencing inflammatory responses[1][3]. It also interacts with neurexins, suggesting a function at neural synapses. Genetic or functional disruption of TAFA4 in animal models affects pain behavior and inflammatory responses, highlighting its role as a potential therapeutic target for neuro-inflammatory disease and pain management[1][2].
Binds to and activates formyl peptide receptor 1 (FPR1), a G protein-coupled receptor, to modulate macrophage chemoattraction, phagocytosis, and inflammation[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chemokine-like protein TAFA-4 (TAFA4).